Understanding how IL-18 affects atopic dermatitis
Defining the role of IL-18 in atopic dermatitis
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11064050
This study is looking at how a substance called IL-18 affects atopic dermatitis, a skin condition that causes itching and inflammation, to help find new ways to treat it.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11064050 on ClinicalTrials.gov |
What this research studies
This research investigates the role of interleukin-18 (IL-18) in atopic dermatitis, a common skin condition characterized by chronic inflammation and itching. The study aims to understand how IL-18 influences the activation of immune cells, particularly basophils and group 2 innate lymphoid cells (ILC2s), which are known to produce type 2 cytokines that drive allergic responses. By analyzing skin samples and using advanced techniques like single-cell RNA sequencing, researchers hope to uncover the mechanisms by which IL-18 contributes to the symptoms of atopic dermatitis. This could lead to new therapeutic strategies targeting IL-18 to alleviate the condition.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of all ages suffering from moderate to severe atopic dermatitis.
Not a fit: Patients with mild atopic dermatitis or those not experiencing significant allergic inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target IL-18, potentially reducing symptoms and improving the quality of life for patients with atopic dermatitis.
How similar studies have performed: Previous research has shown promising results in targeting type 2 cytokines for atopic dermatitis, suggesting that exploring IL-18 could be a valuable and novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VAN DYKEN, STEVEN — WASHINGTON UNIVERSITY
- Study coordinator: VAN DYKEN, STEVEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.